Neuromiol (Rasagiline)

Rasagiline irreversibly inhibits the MAO‑B enzyme in the brain, decreasing the breakdown of dopamine. Higher dopamine levels enhance neuronal signaling in pathways that control movement, thereby alleviating the motor symptoms of Parkinson's disease.

The appropriate dose of Neuromiol is determined by the prescribing physician based on the patient’s clinical condition, disease stage, and response to therapy. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions exactly.

Safety data for rasagiline during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Neuromiol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neuromiol (rasagiline) and selegiline are both MAO‑B inhibitors used in Parkinson's disease. Rasagiline has a longer half‑life, requires once‑daily dosing, and is generally associated with a lower incidence of certain side effects such as orthostatic hypotension compared with selegiline.

Neuromiol tablets should be stored at room temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Neuromiol is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious risks include sudden high blood pressure, hallucinations or other psychotic symptoms, serotonin syndrome when combined with serotonergic drugs, severe liver injury, and allergic reactions such as rash or swelling. Any of these symptoms should prompt immediate medical attention.

Neuromiol is contraindicated in patients with known hypersensitivity to rasagiline or any excipients, those taking other MAO‑A inhibitors, and individuals with severe liver impairment. Caution is also advised for patients with a history of psychiatric disorders or uncontrolled hypertension.